The concept of the 'percent wasted patients' in preventive health strategies

Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacoepidemiology and drug safety 2006-01, Vol.15 (1), p.57-61
Hauptverfasser: Cardinal, Héloise, Monfared, Amir Abbas Tahami, Dorais, Marc, LeLorier, Jacques
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 61
container_issue 1
container_start_page 57
container_title Pharmacoepidemiology and drug safety
container_volume 15
creator Cardinal, Héloise
Monfared, Amir Abbas Tahami
Dorais, Marc
LeLorier, Jacques
description Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of a given preventive treatment, who have discontinued therapy before the time point at which clinical benefits become apparent on the cumulative incidence curves in randomized controlled trials (RCTs) comparing active treatment to placebo. To calculate the PWP, the RCTs that demonstrated the efficacy of the therapy under study must be identified from a MEDLINE search. The point at which the cumulative incidence curves for the main outcome in the experimental and placebo group start diverging is identified and is called the point of visual divergence (PVD). Then, using pharmaceutical claims databases, the percent persistence at the PVD in new users of the therapy is determined. The PWP is then calculated as 100% persistence at PVD. Results For primary prevention with statins, in the province of Quebec, the PWP is 44%. Of 100 patients starting statins for the primary prevention of coronary events, 44 will represent a waste in health resources because they will have discontinued therapy before any clinical benefit can be expected. Conclusions The PWP is a simple measure that can be used by clinicians to select the therapies that need the most reinforcement concerning the importance of persistence. Copyright © 2005 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/pds.1148
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67598913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67598913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3578-69f451edb7e1ac7264f22f3bda7387da4c83eb09d57bc7cb84b802aca7b7eed33</originalsourceid><addsrcrecordid>eNp1kMtOxCAUhonReE98AsPKcVOFUgosvd8maqJG44ZQeupUO9MKjJe3l8k0unJ1-MN3_px8CG1RskcJSfe70u9RmskFtEqJUgnlXCzO3pwlkudqBa15_0pI_FPZMlqhOZFSCbWKhvcjwLadWOgCbiscYhx04CxMAv40PkCJOxPqGP0A1xPcOfiIof4APALThBH2wZkALzX4DbRUmcbDZj_X0cPpyf3ReTK8Obs4OhgmlnEhk1xVGadQFgKosSLNsypNK1aURjApSpNZyaAgquSisMIWMiskSY01Im5Aydg62pn3dq59n4IPelx7C01jJtBOvc4FV1LRGbg7B61rvXdQ6c7VY-O-NSV6Zk5Hc3pmLqLbfee0GEP5B_aqIpDMgc-6ge9_i_Tt8V1f2PN1lPj1yxv3Fu9jguvH6zN9eMnl89UT0cfsB4LOh5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67598913</pqid></control><display><type>article</type><title>The concept of the 'percent wasted patients' in preventive health strategies</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Cardinal, Héloise ; Monfared, Amir Abbas Tahami ; Dorais, Marc ; LeLorier, Jacques</creator><creatorcontrib>Cardinal, Héloise ; Monfared, Amir Abbas Tahami ; Dorais, Marc ; LeLorier, Jacques</creatorcontrib><description>Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of a given preventive treatment, who have discontinued therapy before the time point at which clinical benefits become apparent on the cumulative incidence curves in randomized controlled trials (RCTs) comparing active treatment to placebo. To calculate the PWP, the RCTs that demonstrated the efficacy of the therapy under study must be identified from a MEDLINE search. The point at which the cumulative incidence curves for the main outcome in the experimental and placebo group start diverging is identified and is called the point of visual divergence (PVD). Then, using pharmaceutical claims databases, the percent persistence at the PVD in new users of the therapy is determined. The PWP is then calculated as 100% persistence at PVD. Results For primary prevention with statins, in the province of Quebec, the PWP is 44%. Of 100 patients starting statins for the primary prevention of coronary events, 44 will represent a waste in health resources because they will have discontinued therapy before any clinical benefit can be expected. Conclusions The PWP is a simple measure that can be used by clinicians to select the therapies that need the most reinforcement concerning the importance of persistence. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.1148</identifier><identifier>PMID: 16088979</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Aged ; Drug Utilization ; Female ; Health Resources - economics ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Incidence ; Male ; Middle Aged ; Patient Compliance ; Patient Dropouts ; persistence to therapy ; primary prevention ; Primary Prevention - economics ; Randomized Controlled Trials as Topic ; waste in health resources</subject><ispartof>Pharmacoepidemiology and drug safety, 2006-01, Vol.15 (1), p.57-61</ispartof><rights>Copyright © 2005 John Wiley &amp; Sons, Ltd.</rights><rights>(c) 2005 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3578-69f451edb7e1ac7264f22f3bda7387da4c83eb09d57bc7cb84b802aca7b7eed33</citedby><cites>FETCH-LOGICAL-c3578-69f451edb7e1ac7264f22f3bda7387da4c83eb09d57bc7cb84b802aca7b7eed33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.1148$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.1148$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16088979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cardinal, Héloise</creatorcontrib><creatorcontrib>Monfared, Amir Abbas Tahami</creatorcontrib><creatorcontrib>Dorais, Marc</creatorcontrib><creatorcontrib>LeLorier, Jacques</creatorcontrib><title>The concept of the 'percent wasted patients' in preventive health strategies</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidem. Drug Safe</addtitle><description>Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of a given preventive treatment, who have discontinued therapy before the time point at which clinical benefits become apparent on the cumulative incidence curves in randomized controlled trials (RCTs) comparing active treatment to placebo. To calculate the PWP, the RCTs that demonstrated the efficacy of the therapy under study must be identified from a MEDLINE search. The point at which the cumulative incidence curves for the main outcome in the experimental and placebo group start diverging is identified and is called the point of visual divergence (PVD). Then, using pharmaceutical claims databases, the percent persistence at the PVD in new users of the therapy is determined. The PWP is then calculated as 100% persistence at PVD. Results For primary prevention with statins, in the province of Quebec, the PWP is 44%. Of 100 patients starting statins for the primary prevention of coronary events, 44 will represent a waste in health resources because they will have discontinued therapy before any clinical benefit can be expected. Conclusions The PWP is a simple measure that can be used by clinicians to select the therapies that need the most reinforcement concerning the importance of persistence. Copyright © 2005 John Wiley &amp; Sons, Ltd.</description><subject>Aged</subject><subject>Drug Utilization</subject><subject>Female</subject><subject>Health Resources - economics</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patient Compliance</subject><subject>Patient Dropouts</subject><subject>persistence to therapy</subject><subject>primary prevention</subject><subject>Primary Prevention - economics</subject><subject>Randomized Controlled Trials as Topic</subject><subject>waste in health resources</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOxCAUhonReE98AsPKcVOFUgosvd8maqJG44ZQeupUO9MKjJe3l8k0unJ1-MN3_px8CG1RskcJSfe70u9RmskFtEqJUgnlXCzO3pwlkudqBa15_0pI_FPZMlqhOZFSCbWKhvcjwLadWOgCbiscYhx04CxMAv40PkCJOxPqGP0A1xPcOfiIof4APALThBH2wZkALzX4DbRUmcbDZj_X0cPpyf3ReTK8Obs4OhgmlnEhk1xVGadQFgKosSLNsypNK1aURjApSpNZyaAgquSisMIWMiskSY01Im5Aydg62pn3dq59n4IPelx7C01jJtBOvc4FV1LRGbg7B61rvXdQ6c7VY-O-NSV6Zk5Hc3pmLqLbfee0GEP5B_aqIpDMgc-6ge9_i_Tt8V1f2PN1lPj1yxv3Fu9jguvH6zN9eMnl89UT0cfsB4LOh5Q</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Cardinal, Héloise</creator><creator>Monfared, Amir Abbas Tahami</creator><creator>Dorais, Marc</creator><creator>LeLorier, Jacques</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200601</creationdate><title>The concept of the 'percent wasted patients' in preventive health strategies</title><author>Cardinal, Héloise ; Monfared, Amir Abbas Tahami ; Dorais, Marc ; LeLorier, Jacques</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3578-69f451edb7e1ac7264f22f3bda7387da4c83eb09d57bc7cb84b802aca7b7eed33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Drug Utilization</topic><topic>Female</topic><topic>Health Resources - economics</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patient Compliance</topic><topic>Patient Dropouts</topic><topic>persistence to therapy</topic><topic>primary prevention</topic><topic>Primary Prevention - economics</topic><topic>Randomized Controlled Trials as Topic</topic><topic>waste in health resources</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cardinal, Héloise</creatorcontrib><creatorcontrib>Monfared, Amir Abbas Tahami</creatorcontrib><creatorcontrib>Dorais, Marc</creatorcontrib><creatorcontrib>LeLorier, Jacques</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cardinal, Héloise</au><au>Monfared, Amir Abbas Tahami</au><au>Dorais, Marc</au><au>LeLorier, Jacques</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The concept of the 'percent wasted patients' in preventive health strategies</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidem. Drug Safe</addtitle><date>2006-01</date><risdate>2006</risdate><volume>15</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose To better communicate the impact of poor persistence when preventive therapies are initiated, we propose a new measure that is intuitively understandable for clinicians. This measure is the percent wasted patients (PWP). Methods The PWP is the percentage of patients, out of the new users of a given preventive treatment, who have discontinued therapy before the time point at which clinical benefits become apparent on the cumulative incidence curves in randomized controlled trials (RCTs) comparing active treatment to placebo. To calculate the PWP, the RCTs that demonstrated the efficacy of the therapy under study must be identified from a MEDLINE search. The point at which the cumulative incidence curves for the main outcome in the experimental and placebo group start diverging is identified and is called the point of visual divergence (PVD). Then, using pharmaceutical claims databases, the percent persistence at the PVD in new users of the therapy is determined. The PWP is then calculated as 100% persistence at PVD. Results For primary prevention with statins, in the province of Quebec, the PWP is 44%. Of 100 patients starting statins for the primary prevention of coronary events, 44 will represent a waste in health resources because they will have discontinued therapy before any clinical benefit can be expected. Conclusions The PWP is a simple measure that can be used by clinicians to select the therapies that need the most reinforcement concerning the importance of persistence. Copyright © 2005 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>16088979</pmid><doi>10.1002/pds.1148</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1053-8569
ispartof Pharmacoepidemiology and drug safety, 2006-01, Vol.15 (1), p.57-61
issn 1053-8569
1099-1557
language eng
recordid cdi_proquest_miscellaneous_67598913
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Aged
Drug Utilization
Female
Health Resources - economics
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Incidence
Male
Middle Aged
Patient Compliance
Patient Dropouts
persistence to therapy
primary prevention
Primary Prevention - economics
Randomized Controlled Trials as Topic
waste in health resources
title The concept of the 'percent wasted patients' in preventive health strategies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T00%3A11%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20concept%20of%20the%20'percent%20wasted%20patients'%20in%20preventive%20health%20strategies&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Cardinal,%20H%C3%A9loise&rft.date=2006-01&rft.volume=15&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.1148&rft_dat=%3Cproquest_cross%3E67598913%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67598913&rft_id=info:pmid/16088979&rfr_iscdi=true